首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備 DDS

北美經皮給藥系統市場預測至 2030 年 - 區域分析 - 按類型、應用和配銷通路

市場調查報告書

商品編碼

1510744

北美經皮給藥系統市場預測至 2030 年 - 區域分析 - 按類型、應用和配銷通路

North America Transdermal Drug Delivery System Market Forecast to 2030 - Regional Analysis - by Type, Application, and Distribution Channel

出版日期: 2024年05月07日 | 出版商:

The Insight Partners | 英文 109 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

北美經皮給藥系統市場預計將從2022年的149.7762億美元成長到2030年的209.5837億美元。

慢性病盛行率的增加推動北美經皮給藥系統市場

心絞痛、動脈粥狀硬化、心絞痛和急性心肌梗塞等心血管疾病（CVD）是世界上常見的死因之一。據世界衛生組織稱，CVD 是全球每年約 1,790 萬人死亡的主要原因。許多藥物可用於治療心血管疾病，但傳統的膠囊和片劑無法有效控制疾病。這強調了對新型藥物遞送系統的需求，該系統可提供延長的藥物生物利用度和標靶藥物遞送至心血管系統受影響的區域。與常規口服藥物相比，經皮給藥系統在治療心血管疾病方面具有許多優勢。將含有藥物顆粒的經皮貼片塗抹在皮膚表面。心臟補片為改善細胞植入提供了一個絕佳的平台。例如，最近開發的血管化心臟補片顯示出治療缺血性心臟損傷的巨大潛力。硝酸甘油經皮貼片用於預防冠狀動脈疾病患者的心絞痛（胸痛）發作。它們的作用是放鬆血管並減輕心臟壓力，從而降低對氧氣的需求。然而，這些貼片不能用於治療已經開始的心絞痛發作。

根據阿茲海默症協會的報告，2019年，阿茲海默症在美國主要死因中排名第六，2020年和2021年則排名第七。根據美國國立衛生研究院 2023 年的統計數據，約 670 萬 65 歲及以上的美國人（即每 9 人中就有 1 人，即人口的 10.8%）患有阿茲海默症。患有阿茲海默症的人的比例隨著年齡的成長而增加。 65-74歲的人中有5%、75-84歲的人有13.1%、85歲及以上的人有33.3%患有阿茲海默症。根據2021 年發布的《全球年輕發病失智症盛行率》報告，美國30-64 歲的年輕發病失智症盛行率估計為每10 萬人中就有110 人，即總共約20 萬名美國人。卡巴拉汀貼片用於治療與輕度、中度或重度阿茲海默症相關的失智症（記憶喪失）或與帕金森氏症相關的輕至中度癡呆。卡巴拉汀和多奈哌齊是膽鹼酯酶抑制劑，表現出劑量反應關係，藥物劑量越高，療效越好。它是一種小的親脂性和親水性分子，化學性質非常適合經皮遞送。

糖尿病是一種危及生命的慢性疾病，沒有專門的治療方法。這兩種類型的糖尿病都會導致身體不同部位出現各種問題，並增加過早死亡的整體風險。根據國際糖尿病聯盟（IDF）糖尿病圖譜第10版報告，2021年，全球有5.37億成年人（20-79歲）患有糖尿病，到2030年這一數字可能達到6.43億，到2045年將達到7.83億。然而，最近人們關注的是一種智慧貼片，它可以在需要時提供胰島素，簡化胰島素攝取並激活有針對性的作用。

因此，心血管疾病、阿茲海默症和糖尿病等慢性疾病發生率的增加促進了經皮給藥系統市場的成長。

北美經皮給藥系統市場概況

北美經皮給藥系統市場分為美國、加拿大和墨西哥。 2022年，美國佔據北美經皮給藥系統市場最大佔有率。經皮給藥系統的不斷創新和中樞神經系統疾病的增加是預計在預測期內加速北美經皮給藥系統市場成長的少數因素之一。此外，不斷增加的研發活動和新產品的推出正在推動經皮給藥系統市場的發展。根據美國心臟協會 (AHA) 的數據，心血管疾病 (CVD) 仍然是美國的首要死因。據 CDC 稱，2021 年，CVD 導致美國約 695,000 人死亡，約占美國五分之一的死亡人數。心血管疾病、糖尿病、慢性疼痛和其他慢性疾病的盛行率不斷上升，推動了對有效、便利的治療方案的需求。醫療貼片提供了一種非侵入性且患者友善的方法來提供藥物並管理與這些慢性病相關的症狀。 TDDS 的不斷進步，例如穿戴式感測器和軟性電子產品，有助於經皮給藥系統市場的成長。這些進步可以實現更準確的劑量、增強的患者監測並提高患者的依從性。根據Biomaterials Research 2021年發表的題為《經皮給藥系統的最新進展》的報告，微針在TDDS模式中引起了極大關注，它通過結合微針的優點克服了現有簡單塗抹型和貼片型針的限制。這些TDDS的進展可以為控制心血管和中樞神經系統疾病、糖尿病、神經肌肉疾病以及傳染病和局部傳染病的流行提供動力。

個人化藥物的日益成長的趨勢，即針對個別患者量身定做治療方案，促進了提供受控和有針對性的藥物輸送的醫療貼劑的開發。這種客製化可以改善患者的治療效果並提高治療效果。例如，2020年，Reddy's Laboratories在美國市場推出了授權通用版NitroDur（硝酸甘油）經皮輸注系統。隨著人們對家庭醫療保健和遠端患者監測的日益重視，醫療貼片為在傳統醫療保健環境之外輸送藥物和監測生命徵象提供了便捷的解決方案。美國經皮給藥系統市場受到慢性病盛行率上升、技術進步以及對個人化藥物日益關注等因素的影響。

北美經皮給藥系統市場收入及 2030 年預測（百萬美元）

北美經皮給藥系統市場細分

北美經皮給藥系統市場按類型、應用、配銷通路和國家細分。

根據類型，北美經皮給藥系統市場分為經皮貼片、經皮凝膠、經皮噴霧等。到2022年，經皮凝膠細分市場佔據北美經皮給藥系統市場的最大佔有率。。

在應用方面，北美經皮給藥系統市場細分為心血管疾病、中樞神經系統疾病、疼痛管理、荷爾蒙應用和其他應用。到2022年，疼痛管理領域佔據北美經皮給藥系統市場的最大佔有率。荷爾蒙應用進一步細分為經皮雌激素和黃體素治療以及睪固酮替代療法。

根據配銷通路，北美經皮給藥系統市場分為醫院藥房、零售藥房、線上藥房等。 2022年，醫院藥局部門在北美經皮給藥系統市場中佔據最大佔有率。

依國家分類，北美經皮給藥系統市場分為美國、加拿大和墨西哥。 2022年，美國主導北美經皮給藥系統市場。

Boehringer Ingelheim International GmbH、GSK Plc、Hisamitsu Pharmaceutical Co Inc、Johnson & Johnson、Lavipharm SA、Luye Pharma Group Ltd、Novartis AG、Purdue Pharma LP、UCB SA 和 Viatris Inc 是北美經皮用藥領域的一些領先公司藥物傳輸系統市場。

Cardiovascular diseases (CVDs) such as angina, atherosclerosis, pectoris, and acute myocardial infarction are among the common causes of mortality in the world. According to the WHO, CVDs are the major cause of ~17.9 million deaths worldwide every year. Many medicines are commercially available for the treatment of CVDs but conventional capsules and tablets are unable to effectively control the ailment. This underlines the need for novel drug delivery systems providing prolonged drug bioavailability and targeted drug delivery to the affected areas of the cardiovascular system. Transdermal drug delivery systems offer many advantages over regular orally administered drugs to treat cardiovascular diseases. Transdermal patches, encompassing drug particles, are applied on the skin surface. A cardiac patch provides an excellent platform for cell engraftment improvement. For example, a vascularized cardiac patch developed recently shows promising potential for treating ischemic heart injuries. Nitroglycerin transdermal patches are used to prevent angina (chest pain) episodes in people with coronary artery disease. They work by relaxing the blood vessels and reducing the stress on the heart, thereby lowering the need for oxygen. However, these patches cannot be used to treat angina attacks that have already begun.

According to the Alzheimer's association report, in 2019, Alzheimer disease was ranked sixth and in 2020 and 2021 it was ranked seventh among the leading causes of death in in the US. According to the 2023 stats by the National Institute of Health, ~6.7 million Americans (i.e., 1 in 9 people or 10.8% of the population), aged 65 and older, have Alzheimer's dementia. The percentage of people with Alzheimer's dementia increases with age. 5% of people aged 65-74, 13.1% aged 75-84, and 33.3% aged 85 and above have Alzheimer's dementia. According to the "Global Prevalence of Young-Onset Dementia" report published in 2021, the prevalence of younger-onset dementia in the US is estimated at 110 of every 100,000 people aged 30-64 years, or ~200,000 Americans in total. Rivastigmine patch is used to treat dementia (memory loss) associated with mild, moderate, or severe Alzheimer's disease or mild-to-moderate dementia associated with Parkinson's disease. Rivastigmine and donepezil are cholinesterase inhibitors exhibiting a dose-response relationship, with higher doses of the drugs demonstrating greater efficacy. It is a small, lipophilic, and hydrophilic molecule that is chemically well-suited for transdermal delivery.

Diabetes is a life-threatening chronic disease having no specialized cure. Both types of diabetes can lead to various problems in different body parts and increase the overall risk of premature death. According to the International Diabetes Federation (IDF) Diabetes Atlas 10th edition reports, in 2021, globally 537 million adults (20-79 years) were diabetic, and the number is likely to reach 643 million by 2030 and 783 million by 2045. Exogenous insulin is usually administered subcutaneously for diabetes management. However, the recent attention toward a smart patch that delivers insulin when needed, simplifying insulin intake and activating targeted action.

Thus, the increasing incidences of chronic diseases such as cardiovascular diseases, Alzheimer's disease, and diabetes bolster the growth of the transdermal drug delivery system market.

North America Transdermal Drug Delivery System Market Overview

The North American transdermal drug delivery system market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest share of the North America transdermal drug delivery system market. The growing innovations in the transdermal drug delivery systems and increasing central nervous system disorders are among the few factors projected to accelerate the growth of the North America transdermal drug delivery system market during the forecast period. Moreover, increasing R&D activities and the introduction of novel products are propelling the market for transdermal drug delivery systems. According to the American Heart Association (AHA), cardiovascular disease (CVD) remains the leading cause of death in the US. According to the CDC, in 2021, CVD accounted for ~695,000 deaths and ~1 in 5 deaths in the US. The rising prevalence of cardiovascular disease, diabetes, chronic pain conditions, and other chronic diseases drives the demand for effective and convenient treatment options. Medical patches offer a noninvasive and patient-friendly approach to deliver medication and manage symptoms associated with these chronic conditions. Ongoing advancements in TDDS, such as wearable sensors and flexible electronics, contribute to the growth of the transdermal drug delivery system market. These advancements allow for more accurate dosing, enhanced patient monitoring, and improved patient compliance. According to a report titled "Recent advances in transdermal drug delivery systems," published by Biomaterials Research in 2021, microneedles attract significant attention among TDDS modalities, which overcome the limitations of the existing simple application type and patch-type needles by combining the advantages of microneedles to obtain higher treatment efficiency and effects. Advances in these TDDS can provide the driving force for controlling the prevalence of cardiovascular and central nervous system diseases, diabetes, neuromuscular diseases, and infectious and localized infectious diseases.

The growing trend of personalized medicines, where treatments are tailored to individual patients, has boosted the development of medical patches that offer controlled and targeted drug delivery. This customization allows for better patient outcomes and improved therapeutic efficacy. For instance, in 2020, Reddy's Laboratories launched an Authorized Generic Version of NitroDur (nitroglycerin) Transdermal Infusion System in the US market. With the growing emphasis on home healthcare and remote patient monitoring, medical patches offer a convenient solution for delivering medications and monitoring vital signs outside traditional healthcare settings. The US transdermal drug delivery system market is influenced by factors such as the increasing prevalence of chronic diseases, rising technological advancements, and growing focus on personalized medicines.

North America Transdermal Drug Delivery System Market Revenue and Forecast to 2030 (US$ Million)

North America Transdermal Drug Delivery System Market Segmentation

The North America transdermal drug delivery system market is segmented into type, application, distribution channel, and country.

Based on type, the North America transdermal drug delivery system market is segmented into transdermal patches, transdermal gel, transdermal sprays, and others. The transdermal gel segment held the largest share of the North America transdermal drug delivery system market in 2022. The transdermal patches is further sub segmented into drug-in-adhesive patches, matrix patches, reservoir membrane patches, and vapor patches.

In terms of application, the North America transdermal drug delivery system market is segmented into cardiovascular diseases, central nervous system disorders, pain management, hormonal applications, and other applications. The pain management segment held the largest share of the North America transdermal drug delivery system market in 2022. The pain management is further sub segmented into opioid and non-opioid. The hormonal applications is further sub segmented into transdermal estrogen & progesterone therapy and testosterone replacement.

Based on distribution channel, the North America transdermal drug delivery system market is segmented into hospitals pharmacies, retail pharmacies, online pharmacies, and others. The hospitals pharmacies segment held the largest share of the North America transdermal drug delivery system market in 2022.

Based on country, the North America transdermal drug delivery system market is segmented into the US, Canada, and Mexico. The US dominated the North America transdermal drug delivery system market in 2022.

Boehringer Ingelheim International GmbH, GSK Plc, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Lavipharm SA, Luye Pharma Group Ltd, Novartis AG, Purdue Pharma LP, UCB SA, and Viatris Inc are some of the leading companies operating in the North America transdermal drug delivery system market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Transdermal Drug Delivery System Market - Key Industry Dynamics

4.1 Market Drivers
- 4.1.1 Increasing Prevalence of Chronic Diseases
- 4.1.2 Growing Demand for Noninvasive Drug Delivery Devices
- 4.1.3 High Demand for Self-Administration of Drugs
4.2 Market Restraints
- 4.2.1 Adverse Effects and Recall of Transdermal Drug Delivery Systems
4.3 Market Opportunities
- 4.3.1 Advancements in Smart Patches and 3D-Printed Patches
4.4 Future Trends
- 4.4.1 Strategic Initiatives by Manufacturers
4.5 Impact Analysis

5. Transdermal Drug Delivery System Market - North America Market Analysis

5.1 North America Transdermal Drug Delivery System Market Revenue (US$ Mn), 2022 - 2030

6. North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Type

6.1 Overview
6.2 North America Transdermal Drug Delivery System Market Revenue Share, by Type 2022 & 2030 (%)
6.3 Transdermal Patches
- 6.3.1 Overview
- 6.3.2 Transdermal Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.1 Drug-in-Adhesive Patches
    - 6.3.2.1.1 Overview
    - 6.3.2.1.2 Drug-in-Adhesive Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.2 Matrix Patches
    - 6.3.2.2.1 Overview
    - 6.3.2.2.2 Matrix Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.3 Reservoir Membrane Patches
    - 6.3.2.3.1 Overview
    - 6.3.2.3.2 Reservoir Membrane Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.4 Vapor Patches
    - 6.3.2.4.1 Overview
    - 6.3.2.4.2 Vapor Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Transdermal Gels
- 6.4.1 Overview
- 6.4.2 Transdermal Gels: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Transdermal Sprays
- 6.5.1 Overview
- 6.5.2 Transdermal Sprays: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Others
- 6.6.1 Overview
- 6.6.2 Others: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Application

7.1 Overview
7.2 North America Transdermal Drug Delivery System Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Cardiovascular Diseases
- 7.3.1 Overview
- 7.3.2 Cardiovascular Diseases: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Central Nervous System Disorders
- 7.4.1 Overview
- 7.4.2 Central Nervous System Disorders: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Pain Management
- 7.5.1 Overview
- 7.5.2 Pain Management: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.5.2.1 Opioid
    - 7.5.2.1.1 Overview
    - 7.5.2.1.2 Opioid: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.5.2.2 Non-Opioid
    - 7.5.2.2.1 Overview
    - 7.5.2.2.2 Non-Opioid: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Hormonal Applications
- 7.6.1 Overview
- 7.6.2 Hormonal Applications: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.6.2.1 Transdermal Estrogen & Progesterone Therapy
    - 7.6.2.1.1 Overview
    - 7.6.2.1.2 Transdermal Estrogen & Progesterone Therapy: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.6.2.2 Testosterone Replacement
    - 7.6.2.2.1 Overview
    - 7.6.2.2.2 Testosterone Replacement: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Other Application
- 7.7.1 Overview
- 7.7.2 Other Application: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 North America Transdermal Drug Delivery System Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
- 8.4.1 Overview
- 8.4.2 Retail Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
- 8.5.1 Overview
- 8.5.2 Online Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 - Country Analysis

9.1 North America Transdermal Drug Delivery System Market
- 9.1.1 North America Transdermal Drug Delivery System Market, by Country, 2022 & 2030 (%)
  - 9.1.1.1 US: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.1 Overview
    - 9.1.1.1.2 US: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.3 US: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
    - 9.1.1.1.3.1 US: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
    - 9.1.1.1.4 US: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
    - 9.1.1.1.4.1 US: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
    - 9.1.1.1.4.2 US: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
    - 9.1.1.1.5 US: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.2 Canada: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.1 Overview
    - 9.1.1.2.2 Canada: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.3 Canada: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
    - 9.1.1.2.3.1 Canada: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
    - 9.1.1.2.4 Canada: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
    - 9.1.1.2.4.1 Canada: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
    - 9.1.1.2.4.2 Canada: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
    - 9.1.1.2.5 Canada: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.3 Mexico: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 Overview
    - 9.1.1.3.2 Mexico: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.3 Mexico: North America Transdermal Drug Delivery System Market, by Type, 2020-2030 (US$ Million)
    - 9.1.1.3.3.1 Mexico: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type, 2020-2030 (US$ Million)
    - 9.1.1.3.4 Mexico: North America Transdermal Drug Delivery System Market, by Application, 2020-2030 (US$ Million)
    - 9.1.1.3.4.1 Mexico: North America Transdermal Drug Delivery System Market, For Pain Management by Application, 2020-2030 (US$ Million)
    - 9.1.1.3.4.2 Mexico: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application, 2020-2030 (US$ Million)
    - 9.1.1.3.5 Mexico: North America Transdermal Drug Delivery System Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Transdermal Drug Delivery System Market Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Transdermal Drug Delivery System Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Johnson & Johnson
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 GSK Plc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Viatris Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Boehringer Ingelheim International GmbH
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Hisamitsu Pharmaceutical Co Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Luye Pharma Group Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Lavipharm SA
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Purdue Pharma LP
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 UCB SA
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. North America Transdermal Drug Delivery System Market Segmentation
Table 2. US: North America Transdermal Drug Delivery System Market, by Type - Revenue and Forecast to 2030 (US$ Million)
Table 3. US: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type - Revenue and Forecast to 2030 (US$ Million)
Table 4. US: North America Transdermal Drug Delivery System Market, by Application - Revenue and Forecast to 2030 (US$ Million)
Table 5. US: North America Transdermal Drug Delivery System Market, For Pain Management by Application - Revenue and Forecast to 2030 (US$ Million)
Table 6. US: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application - Revenue and Forecast to 2030 (US$ Million)
Table 7. US: North America Transdermal Drug Delivery System Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 8. Canada: North America Transdermal Drug Delivery System Market, by Type - Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type - Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada: North America Transdermal Drug Delivery System Market, by Application - Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada: North America Transdermal Drug Delivery System Market, For Pain Management by Application - Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application - Revenue and Forecast to 2030 (US$ Million)
Table 13. Canada: North America Transdermal Drug Delivery System Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico: North America Transdermal Drug Delivery System Market, by Type - Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico: North America Transdermal Drug Delivery System Market, For Transdermal Patches by Type - Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico: North America Transdermal Drug Delivery System Market, by Application - Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico: North America Transdermal Drug Delivery System Market, For Pain Management by Application - Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico: North America Transdermal Drug Delivery System Market, For Hormonal Applications by Application - Revenue and Forecast to 2030 (US$ Million)
Table 19. Mexico: North America Transdermal Drug Delivery System Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 20. Recent Inorganic Growth Strategies in the Transdermal Drug Delivery System Market
Table 21. Recent Organic Growth Strategies in the Transdermal Drug Delivery System Market
Table 22. Glossary of Terms, North America Transdermal Drug Delivery System Market

List Of Figures

Figure 1. North America Transdermal Drug Delivery System Market Segmentation, By Country
Figure 2. North America Transdermal Drug Delivery System Market: Key Industry Dynamics
Figure 3. North America Transdermal Drug Delivery System Market: Impact Analysis of Drivers and Restraints
Figure 4. North America Transdermal Drug Delivery System Market Revenue (US$ Mn), 2020 - 2030
Figure 5. North America Transdermal Drug Delivery System Market Revenue Share, by Type 2022 & 2030 (%)
Figure 6. Transdermal Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Drug-in-Adhesive Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Matrix Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Reservoir Membrane Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Vapor Patches: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Transdermal Gels: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Transdermal Sprays: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America Transdermal Drug Delivery System Market Revenue Share, by Application 2022 & 2030 (%)
Figure 15. Cardiovascular Diseases: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Central Nervous System Disorders: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Pain Management: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Opioid: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Non-Opioid: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Hormonal Applications: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Transdermal Estrogen & Progesterone Therapy: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 22. Testosterone Replacement: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Other Application: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. North America Transdermal Drug Delivery System Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 25. Hospital Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 26. Retail Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 27. Online Pharmacies: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. Others: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. North America Transdermal Drug Delivery System Market, by Key Country - Revenue (2022) (US$ Million)
Figure 30. North America: North America Transdermal Drug Delivery System Market, by Country, 2022 & 2030 (%)
Figure 31. US: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 32. Canada: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 33. Mexico: North America Transdermal Drug Delivery System Market - Revenue and Forecast to 2030 (US$ Million)
Figure 34. Growth Strategies in the Transdermal Drug Delivery System Market